Telesso Technologies Limited (ASX: TEO) today launched a $6.5 million capital raising in connection with its acquisition of IMB spin-out company Mimetica and its relisting on the Australian Securities Exchange (ASX).
The funds will be used to support the Phase 2 clinical trial of Mimetica's potential breakthrough topical acne treatment MTC896.
Read more on the ASX website.
